Erythroferrone Modulates Osteoblast-Osteoclast Crosstalk During Bone Remodeling

Erythroferrone (ERFE) secretion inhibits hepcidin expression by sequestering several bone morphogenetic protein (BMP) family members to increase iron availability for erythropoiesis. Recent evidence demonstrates that ERFE is also expressed in osteoblasts and osteoclasts and Erfe ^−/− mice display low–bone–mass arising from increased bone resorption despite a concomitant increase in bone formation. To mechanistically dissect how bone–derived ERFE exerts an osteoprotective effect, we first created Erfe ^fl/fl mice, which were then crossed with Col2.3 -Cre mice to generate osteoblast–selective Erfe mutants (or Erfe ^fl/fl ; Col2.3 -Cre mice). We now demonstrate that ERFE derived from osteoblasts is not responsible for the decreased BMD noted in Erfe ^−/− mice, revealing enhanced BMD during anabolic stress in Erfe ^fl/fl ; Col2.3 -Cre mice. Consistently, in contrast to global ERFE loss, osteoblast–selective ERFE loss does not increase osteoclasts in vivo . Furthermore, our results demonstrate that ERFE loss in osteoblasts induces osteoclast Erfe expression in co-culture experiments in vitro . Finally, the osteoclastogenesis gene program is induced in co-culture with osteoblasts only when ERFE is lost in osteoclasts. Taken together, our finding provide strong evidence of osteoclast–derived ERFE as a central osteoprotective regulator of bone mass, its loss resulting in net bone loss in Erfe ^−/− mice.